18F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer

Urology

Volumn 83, Issue 2, 2014, Pages 393-399

  Mertens, Laura S ^a   Mir, M Carmen ^b   Scott, Andrew M ^b   Lee, Sze Ting ^b   Fioole Bruining, Annemarie ^c   Vegt, Erik ^c   Vogel, Wouter V ^c   Manecksha, Rustom ^b   Bolton, Damien ^b   Davies, Ian ^d   Horenblas, Simon ^a   Van Rhijn, Bas W G ^a   Lawrentschuk, Nathan ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PET-CT SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLADDER TUMOR; COMPUTER ASSISTED TOMOGRAPHY; MORTALITY; MULTICENTER STUDY; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGNOSIS; SMOOTH MUSCLE; TUMOR INVASION;

AGED; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MULTIMODAL IMAGING; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 84893163141     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.10.032     Document Type: Article

References (21)

1. Jemal A. Cancer statistics, 2009. 2009.
2. J.P. Stein, G. Lieskovsky, and R. Cote et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
3. A. Stenzl, N.C. Cowan, and M. De Santis et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
4. R.E. Hautmann, R.C. de Petriconi, C. Pfeiffer, and B.G. Volkmer Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients Eur Urol 61 2012 1039 1047
5. M.L. Paik, M.J. Scolieri, and S.L. Brown et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy J Urol 163 2000 1693 1696
6. A.B. Apolo, J. Riches, and H. Schoder et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer J Clin Oncol 28 2010 3973 3978
7. O. Drieskens, R. Oyen, and H. Van Poppel et al. FDG-PET for preoperative staging of bladder cancer Eur J Nucl Med Mol Imaging 32 2005 1412 1417
8. A.S. Kibel, F. Dehdashti, and M.D. Katz et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 27 2009 4314 4320
9. M. Lodde, L. Lacombe, and J. Friede et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma BJU Int 106 2010 658 663
10. Y.Y. Lu, J.H. Chen, and J.A. Liang et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysis Eur J Radiol 81 2012 2411 2416
11. L.H. Sobin, M.K. Gospodarowicz, and Ch Wittekind TNM Classification of Malignant Tumours 7th ed. 2009 Wiley-Blackwell
12. R.R. De Vries, J.A. Nieuwenhuijzen, and W. Meinhardt et al. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only Eur J Surg Oncol 35 2009 352 355
13. J.J. Shuster Median follow-up in clinical trials J Clin Oncol 9 1991 191 192
14. G. Swinnen, A. Maes, and H. Pottel et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer Eur Urol 57 2010 641 647
15. 18F-fluorodexoyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int. 2013;112:729-734.
16. R.S. Gillies, M.R. Middleton, and C. Han et al. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma Br J Surg 99 2012 239 245
17. P.W. Grigsby, B.A. Siegel, and F. Dehdashti Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J Clin Oncol 19 2001 3745 3749
18. D. Hong, S. Lunagomez, and E.E. Kim et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma Cancer 104 2005 1620 1626
19. C.T. Liao, H.M. Wang, and S.F. Huang et al. PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity J Nucl Med 52 2011 180 187
20. S. Peters, A.A. Adjei, and C. Gridelli et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii56 vii64
21. F. Cardoso, N. Harbeck, and L. Fallowfield et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii11 vii19